Clinical trial
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
NCT00495339 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00495339 |
|---|---|
| Title | MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis |
| Official title | Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Tuberculosis, Pulmonary |
| Intervention type | Drug |
| Interventions | Levofloxacin |
| Enrollment | 100 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2008 |
| First posted | Jul 3, 2007 |
| Last update posted | Mar 4, 2009 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: